ESMO 2023
DATO-DX - where is it going?
BEGONIA, TROPION-01 Breast
ESMO 2023
DATO-DX - where is it going?
CheckMate 7FL
ESMO 2023
Preoperative checkpointinihition in ER+ disease
TROPION-Breast01, DESTINY-Breast-01, -02, 03, IMPACT
ESMO 2023
My highlights of ESMO23 in metastatic breast cancer
monarchE, KEYNOTE-522, KEYNOTE-756, CheckMate 7FL
ESMO 2023
Highlights in eBC
DESTINY-Breast-01, -02, -03
ESMO 2023
Remarkable efficacies in patients with HER2+ mBC with…
monarchE
ESMO 2023
5 year follow-up
EV-302/KEYNOTE-A39
ESMO 2023
When the history of ADC is written: Redefining…
RENOTORCH
ESMO 2023
Clearing up non-clear cell RCC
LITESPARK-005
ESMO 2023
New 3rd line therapy for RCC
EMBARK
ESMO 2023
Early use of enzalutamide in advanced prostate cancer
THOR, THOR-2
ESMO 2023
The FGFR story in bladder cancer at ESMO23
PSMAfore, ENZA-p
ESMO 2023
Lu-PSMA leads forward
ALINA
ESMO 2023
ALINA - immediate change of practice!
TROPION-Lung1
ESMO 2023
Datopotamab deruxtecan - new SOC in 2nd line adv/met…
DeLLphi-301
ESMO 2023
Tarlatamab in SCLC
CheckMate 816, CheckMate 77T, ALINA, PAPILLON, MARIPOSA, MARIPOSA-2
ESMO 2023
My highlights from ESMO 2023
PAPILLON
ESMO 2023
Amivantamab as a new SoC for EGFR Exon 20…
KEYNOTE-671
ESMO 2023
Perioperativ immunotherapy for all resectable stage…
ESMO 2023
What is your definition of triple-negative breast…
monarchE, Keynote-756, CheckMate 7FL
ESMO 2023
Anticipated updates and exciting new data for…
Natalee, monarchE
ESMO 2023
Data updates for CDK4/6 inhibitors in EBC at ESMO23 -…
Keynote-522, NeoTrip
ESMO 2023
New and better biomarkers are needed!
DESTINY-Breast-01, -02, -03; IMPACT; CheckMate 7FL; KEYNOTE-756; TROPION-Breast01; BEGONIA; DESTINY-Breast 04
ESMO 2023
What was the most exciting news at ESMO23?
Keynote-522
ESMO 2023
Pembrolizumab solidifies as SOC in early-stage TNBC
NeoTrip
ESMO 2023
Negative EFS results from NeoTrip
MonarchE
ESMO 2023
MonarchE - trial update
MonarchE, KEYNOTE-522
ESMO 2023
Consolidation of data in early HR+ and triple-negative…
NeoMET
ESMO 2023
Metabolomics reveal differential expression of OMEGA 3…
KEYNOTE-756, CheckMate 7FL, monarchE, KEYNOTE-522
ESMO 2023
My highlights of ESMO23 in early breast cancer
Keynote-756, CheckMate 7FL
ESMO 2023
Neoadjuvant IO - is their new strategy in HR+ breast…
ADAPT
ESMO 2023
Prognostic score in early HR+/HER2-BC: translational…
NATALEE
ESMO 2023
Detailed view of nodal-negative patients
ESMO 2023
Analysis of tumour microenvironment and…
monarchE
ESMO 2023
5 year follow-up
NATALEE
ESMO 2023
Ribociclib effective in all subtypes
ESMO 2023
ER-low corresponds diagnostically to ER-0 breast cancer
CheckMate 7FL
ESMO 2023
Preoperative checkpointinihition in ER+ disease
Keynote-522
ESMO 2023
Clinically relevant effect of pembro also in PCR
monarchE, KEYNOTE-522, Destiny-Breast 04
ESMO 2023
Our guidelines are correct
Keynote-756, CheckMate 7FL
ESMO 2023
New data on neoadjuvant immunotherapy
KEYNOTE-756; CheckMate 7FL
ESMO 2023
Use of immunotherapy in the perioperative setting of…
monarchE
ESMO 2023
Carry-over effects in monarchE confirmed
KEYNOTE-522
ESMO 2023
Immunoncology in eBC - triple negative and more?
KEYNOTE-756, KEYNOTE-522
ESMO 2023
HR+ study with > 20 % PCR
monarchE, KEYNOTE-522, KEYNOTE-756, CheckMate 7FL
ESMO 2023
Highlights in eBC
MonarchE
ESMO 2023
MonarchE - mise à jour de l'essai
Keynote-756, CheckMate 7FL
ESMO 2023
Nouvelles données sur l'immunothérapie néoadjuvante
monarchE, KEYNOTE-522, KEYNOTE-756, CheckMate 7FL
ESMO 2023
Punti salienti in eBC
NeoTrip
ESMO 2023
Studio NeoTrip: negativi i risultati
NeoMET
ESMO 2023
La Metabolomica svela l’importanza di OMEGA 3 & OMEGA 6…
DESTINY Breast -01, -02, -03, TULIP, DESTINY Breast 04, BEGONIA
ESMO 2023
ADCs in HER2+, HER2low and TNBC - what is the future of…
DESTINY-Breast-01, -02, -03; IMPACT; CheckMate 7FL; KEYNOTE-756; TROPION-Breast01; BEGONIA; DESTINY-Breast 04
ESMO 2023
What was the most exciting news at ESMO23?
IMPACT
ESMO 2023
Improvement of therapy outcome by app-based patient…
TROPION-01 BREAST
ESMO 2023
New ADC for metastatic breast cancer?
SOLTI-1903 HOPE
ESMO 2023
How to organize a molecular tumorboards in breast…
HS20089
ESMO 2023
New targets, new linker, new ADCs - much more to learn…
SOLTI-1903 HOPE
ESMO 2023
Patient-centered molecular medicine - a new approach
monarchE
ESMO 2023
Robust data from the monarchE
TROPiCS-02
ESMO 2023
Benefit for SG even after intensive pretreatment
DESTINY Breast -01, -02, -03
ESMO 2023
T-DXd also effective for brain metastases
PHERgain
ESMO 2023
TROP2 expression as a potential mechanism of resistance…
TROPION-Breast-01
ESMO 2023
Dato-DXd - new player in advanced luminal disease
BEGONIA
ESMO 2023
Duvalumab + Dato-DXd effective
ESMO 2023
OP-1250 (Palezestrant) confirms the role of SIRDs after…
DESTINY-Breast 04, HS-20089, TROPION-Breast01, DESTINY-Breast-01, -02, 03
ESMO 2023
Highlights in mBC
TROPION-Breast01, DESTINY-Breast-01, -02, 03, IMPACT
ESMO 2023
My highlights of ESMO23 in metastatic breast cancer
FALCON
ESMO 2023
Fulvestran better than anastrozole, but no survival…
BEGONIA, TROPION-01 Breast
ESMO 2023
DATO-DX - where is it going?
TROPiON-Breast01
ESMO 2023
New ADC in HR+ disease
monarchE
ESMO 2023
Abemaciclib remains consistent in 5-year follow-up
monarchE, KEYNOTE-522, Destiny-Breast 04
ESMO 2023
Our guidelines are correct
DESTINY-Breast-01, -02, -03
ESMO 2023
T-DXd - new standard of care for brain mets?
DESTINY-breast 1, 2, 3
ESMO 2023
T-DXd in HER2+ patients with brain metastases
BEGONIA
ESMO 2023
ADC + Immunotherapy - the BEGONIA study paradigm
ESMO 2023
OP seems to be dispensable for super responders
IMPACT
ESMO 2023
Improved oncological therapy with the smartphone
ESMO 2023
Can surgery be spared following primary systemic…
BEGONIA
ESMO 2023
Even more new generation ADCs in breast cancer?
Destiny Breast 04
ESMO 2023
Still on track for success in HER2-low MBC
DESTINY-Breast-01, -02, -03
ESMO 2023
Remarkable efficacies in patients with HER2+ mBC with…
HS-20089
ESMO 2023
HS20089 - a novel ADC is coming for TNBC
TULIP
ESMO 2023
TULIP: Trastuzumab duocarmazine without OS benefit
PHERgain
ESMO 2023
HER2DX in the PHERgain trial
ESMO 2023
Czy możliwa jest rezygnacja z chirurgii po indukcyjnym…
PHERgain
ESMO 2023
La expresión de TROP2 como potencial mecanismo de…
BEGONIA
ESMO 2023
Lo studio BEGONIA nelle paziento con tumore triplo…
TROPION-Breast-01
ESMO 2023
Dato-DXd - nowy gracz w zaawansowanym raku luminalnym
HS-20089
ESMO 2023
HS20089 - un nuovo ADC che si affaccia sulla scenda del…
BEGONIA
ESMO 2023
ADC + Immunothérapie: L'exemple de l'étude BEGONIA par…
PHERgain
ESMO 2023
HER2DX en el estudio PHERgain
DESTINY-Breast 04, HS-20089, TROPION-Breast01, DESTINY-Breast-01, -02, 03
ESMO 2023
Punti salienti in mBC
DESTINY-Breast-01, -02, -03
ESMO 2023
T-DXd - nowy standard postępowania w przerzutach do…
ESMO 2023
OP-1250 (Palezestrant) ulteriore conferma del ruolo dei…
PSMAfore, ENZA-p
ESMO 2023
Targeted therapy will move forward - but more robust…
RADICALS RT, EMBARK
ESMO 2023
The optimal timing of RT after radical prostatectomy…
STAMPEDE
ESMO 2023
Should we use zoledronic acid in all ADT patients?
KEYNOTE-641, KEYNOTE-991, AMG509
ESMO 2023
What is the future of immune therapy in prostate…
MAGNITUDE
ESMO 2023
Precision medicine at mCRCP
TITAN
ESMO 2023
TITAN: ultra-low PSA = best prognosis
PSAMfore
ESMO 2023
PSMAfore unleashes urooncologic opportunity
KEYNOTE-641, KEYNOTE-991
ESMO 2023
Negative data for pembrolizumab in mHSCPC & mCRPC
PSMAfore
ESMO 2023
PSMA FORE: Trial and controversies
ESMO 2023
Big data and AI prediction tools
STAMPEDE
ESMO 2023
STAMPEDE. Bone prediction not for everyone - better…
AMG509
ESMO 2023
Brave New World in mCRPC
RADICALS RT
ESMO 2023
Longterm toxicity of adjuvant RT after prostatectomy
KEYNOTE-461, KEYNOTE-991
ESMO 2023
IO therapy in metastatic prostate cancer.
EMBARK
ESMO 2023
Embark without fear
EMBARK
ESMO 2023
Early use of enzalutamide in advanced prostate cancer
STAMPEDE
ESMO 2023
Osteoprotection at mHSPC
RADICALS RT
ESMO 2023
RADICALS RT: Trial and controversies
EMBARK
ESMO 2023
EMBARK - Quality of Life
ENZA-p
ESMO 2023
Combination of radioligand therapy with chemotherapy…
KEYNOTE-641; KEYNOTE-991
ESMO 2023
When immunotherapy is probably not the best choice: The…
PSMAfore, ENZA-p
ESMO 2023
Lu-PSMA leads forward
EMBARK
ESMO 2023
EMBARK expands ENZA indication to PCa
RADICALS RT
ESMO 2023
Salvage radiotherapy the new standard
KEYNOTE-641, KEYNOTE-991
ESMO 2023
Immunotherapy in metastatic PCa
ENZA-p
ESMO 2023
ENZA P:Trial and controversies
CXCR2-inhbitors
ESMO 2023
CXCR2 inhibitor in PCa
EMBARK
ESMO 2023
EMBARK och livskvalitet
KEYNOTE-641; KEYNOTE-991
ESMO 2023
Cuando la inmunoterapia probablemente no es la mejor…
STAMPEDE
ESMO 2023
STAMPEDE data. Skelettstärkande och riskstratifiering.
ESMO 2023
Big Data och AI för prediktion vid prostatacancer
CXCR2-inhbitors
ESMO 2023
CXCR2 hämmare och prostatacancer
KEYNOTE-641, KEYNOTE-991
ESMO 2023
Immunterapi vid prostatacancer
CheckMate 901
ESMO 2023
Part1: New standard of care in first line urothelial…
THOR-2, DAD
ESMO 2023
FGFR inhibitors and ADC combinations in urothelial…
EV-302/KeynoteA38
ESMO 2023
Part 2: New standard of care in first line urothelial…
EV-302/KEYNOTE-A39
ESMO 2023
When the history of ADC is written: Redefining…
THOR; THOR-2; EV-302/KEYNOTE-A39; CheckMate 901
ESMO 2023
Amazing new data in bladder cancer
EV-302/KEYNOTE-A39
ESMO 2023
EV + Pembro as standard of care in first-line therapy…
THOR; THOR-2
ESMO 2023
FGFR inhibitors: What is the best scenario for this…
CheckMate 901
ESMO 2023
Chemo-IO establishes itself in the first-line treatment…
EV-302/KEYNOTE-A39, CheckMate-901
ESMO 2023
New SoC in firstline bladder cancer
THOR, THOR-2
ESMO 2023
The FGFR story in bladder cancer at ESMO23
DAD
ESMO 2023
DAD, DAD-IO
TSA-200
ESMO 2023
Unique bladder delivery system of gemcitabine herolds…
THOR, THOR-2
ESMO 2023
L'histoire du FGFR dans le cancer de la vessie à…
THOR; THOR-2
ESMO 2023
Inhibidores de FGFR: Cual es el mejor escenario para…
THOR; THOR-2; EV-302/KEYNOTE-A39; CheckMate 901; LITESPARK-003; LITESPARK-005; RENOTORCH
ESMO 2023
Στιγμιότυπα για τον καρκίνο των νεφρών και της…
EV-302/KEYNOTE-A39
ESMO 2023
Reescribiendo la historia de una enfermedad: Nuevo…
LITESPARK-005
ESMO 2023
Important new treatment option but only for subset of…
TIDE-A
ESMO 2023
Is de-escalating therapy ready for prime-time?
MEDI5752
ESMO 2023
Where does the future therapy go in renal cell…
LITESPARK-005
ESMO 2023
Belzutifan in later lines of therapy
TIDE-A
ESMO 2023
Intermittent therapy also possible with TKIs
LITESPARK-005
ESMO 2023
New 3rd line therapy for RCC
LITESPARK-003; LITESPARK-005; RENOTORCH
ESMO 2023
Kidney cancer highlights at ESMO23
LITESPARK-003, LITESPARK-005, LITESPARK-013
ESMO 2023
New mode of action in mRCC - ready for prime time?
RENOTORCH
ESMO 2023
Clearing up non-clear cell RCC
LITESPARK-03, LITESPARK-05
ESMO 2023
Belzutifan - whats next kidney cancer?
CheckMate 816; Keynote-671; CheckMate 77T
ESMO 2023
Moving patients to the neoadjuvant setting in…
ALINA
ESMO 2023
ALINA - remarkably positive DFS in early-stage ALK+…
KEYNOTE-671
ESMO 2023
Perioperativ immunotherapy for all resectable stage…
KEYNOTE-671, CheckMate 77T, CheckMate 816
ESMO 2023
Neoadjuvant chemo-immunotherapy new standards in early…
ALINA
ESMO 2023
Adjuvant alectinib in patients with early-stage ALK+…
ALINA
ESMO 2023
ALINA - a new paradigm in operated NSCLC with…
KEYNOTE-671
ESMO 2023
Perioperative IO: OS-benefi from KEYNOTE-671
CheckMate 816, CheckMate 77T, ALINA, PAPILLON, MARIPOSA, MARIPOSA-2
ESMO 2023
My highlights from ESMO 2023
ALINA
ESMO 2023
Substantial improvement in local regional NSCLC
KEYNOTE-671; CheckMate 77T; ALINA; LIBRETTO-431
ESMO 2023
Big improvements in early stage and a subset of…
AEGEAN
ESMO 2023
Circulating DNA in AEGEAN trial
ALINA
ESMO 2023
ALINA - immediate change of practice!
KEYNOTE-671, CheckMate 77T
ESMO 2023
Scene is set for inductive immunotherapy
ALINA
ESMO 2023
ALINA - un nouveau paradigme dans cBNPC avec la fusion…
CheckMate 816, CheckMate 77T, ALINA, PAPILLON, MARIPOSA, MARIPOSA-2
ESMO 2023
Les points forts de l'ESMO 2023
CheckMate 816, CheckMate 77T, ALINA, PAPILLON, MARIPOSA, MARIPOSA-2
ESMO 2023
I miei punti salienti di ESMO 2023
KEYNOTE-671
ESMO 2023
Perioperatieve chemo-immunotherapie voor alle patienten…
KEYNOTE-671; CheckMate 77T; ALINA; LIBRETTO-431
ESMO 2023
Gros progrès dans les traitments medicaeux des stades…
TROPION-Lung01, TROPION-Lung05
ESMO 2023
Evolving landscape of ADCs
ESMO 2023
ESMO2023-impact on everyday practice!
PAPILLON; LIBRETTO-431
ESMO 2023
Rare oncogenic alterations: landmark results on exon 20…
MARIPOSA, MARIPOSA-2, PAPILLON, FLAURA2
ESMO 2023
Activating EGFR-mutation - what's coming up?
CheckMate 816, CheckMate 77T, ALINA, PAPILLON, MARIPOSA, MARIPOSA-2
ESMO 2023
My highlights from ESMO 2023
KEYNOTE-671; CheckMate 77T; ALINA; LIBRETTO-431
ESMO 2023
Big improvements in early stage and a subset of…
PAPILLON
ESMO 2023
Practice changing results on exon 20 insertion mNSCLC
MARIPOSA II
ESMO 2023
MARIPOSA II: Trial and controversies
MARIPOSA-2
ESMO 2023
Amivantamab at progression? MARIPOSA-2 trial
MARIPOSA
ESMO 2023
MARIPOSA: Trial and controversies
MARIPOSA ,MARIPOSA-2
ESMO 2023
Treatment sequences for EGFR-mutated Patients
MARIPOSA
ESMO 2023
Amivantamab upfront? MARIPOSA trial
KRYSTAL-7
ESMO 2023
Adagrasib + pembrolizumab in patients with KRASG12C…
ATTLAS
ESMO 2023
Does immunotherapy still have a place in EGFR-positive…
HERTHENA-Lung01
ESMO 2023
Do ADCs have brain activity?
TROPION-Lung1
ESMO 2023
Datopotamab deruxtecan - new SOC in 2nd line adv/met…
PAPILLON
ESMO 2023
PAPILLON - bringing together therapy for the 1st line
ESMO 2023
NRG fusions: a new drugable target?
MARIPOSA; MARIPOSA-2
ENMO 2023
Changing treatment landscape in EGFR-mutated NSCLC
LIBRETTO-431
ESMO 2023
LIBRETO - a positive study, but was it necessary?
LIBRETTO-431
ESMO 2023
RET-TKI: Standard in 1st line RET fusion-positive NSCLC
FLAURA-2, HERTHENA-Lung01, TROPION-Lung05
ESMO 2023
Brain metastases – options to improve the systemic…
LIBRETTO-431, PAPILLON
ESMO 2023
Substantial improvement in rare alterations
TROPION-Lung01
ESMO 2023
TROPION-Lung01: positive development
PAPILLON
ESMO 2023
New standard of care for metastatic EGFR exon 20…
PAPILLON
ESMO 2023
Amivantamab as a new SoC for EGFR Exon 20…
SAPPHIRE
ESMO 2023
By unanimous decision and still the champion –…
PAPILLON
ESMO 2023
L’amivantamab, nouveau standard de traitement pour les…
MARIPOSA
ESMO 2023
Amivantamab upfront? MARIPOSA trial
MARIPOSA; MARIPOSA-2
ESMO 2023
Veränderte Behandlungslandschaft bei EGFR-mutiertem…
TROPION-Lung1
ESMO 2023
Datopotamab deruxtecan - new SOC in 2nd line adv/met…
KEYNOTE-671; CheckMate 77T; ALINA; LIBRETTO-431
ESMO 2023
Gros progrès dans les traitments medicaeux des stades…
MARIPOSA-2
ESMO 2023
Amivantamab at progression? MARIPOSA-2 trial
MARIPOSA, MARIPOSA-2
ESMO 2023
Quelles séquences thérapeutiques pour les patients EGFR…
PAPILLON
ESMO 2023
Nieuwe standaard voor gemetastaseerd EGFR exon20…
CheckMate 816, CheckMate 77T, ALINA, PAPILLON, MARIPOSA, MARIPOSA-2
ESMO 2023
Les points forts de l'ESMO 2023
CheckMate 816, CheckMate 77T, ALINA, PAPILLON, MARIPOSA, MARIPOSA-2
ESMO 2023
I miei punti salienti di ESMO 2023
ATTLAS
ESMO 2023
Heeft immunotherapie nog een plek in de behandeling van…
DeLLphi-301, TROPiCS-03
ESMO 2023
Impact of T-cell engagers in SCLC
DeLLphi-301
ESMO 2023
New hope for patients with SCLC
DeLLphi-301
ESMO 2023
Tarlatamab in SCLC
DeLLphi-301
ESMO 2023
A new option in relapsed SCLC
DeLLphi-301
ESMO 2023
Neue Hoffnung für Patienten mit SCLC
CUPISCO, CUP-ONE
ESMO 2023
Precision oncology in CUP
OMET; INTERLINK-1
ESMO 2023
New data on H&N Cancer
RUBY
ESMO 2023
Evolution of the revolution - the RUBY trial
ESMO 2023
First data on luveltamab in multiline treatment for…
MEDISARC; TOMAS2
ESMO 2023
New data on sarkomas
FLAMES
ESMO 2023
Update on gynaecological cancers
ESMO 2023
PCO Therapeutics
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!